ASCO Conference Coverage

ASCO Abstract: What Defines Quality Lung Cancer Care?

(ACCCBuzz Blog) June 12, 2020 - At the recent American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, ACCC presented seven abstracts that capture data spanning the organization’s diverse provider education portfolio.

read article

Immunotherapy and Molecular Ways to Measure Response for Thoracic Cancers and Melanoma Featured at Annual Meeting of American Society of Clinical Oncology

(Johns Hopkins) June 10, 2020 - Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for cancer patients.

read press release

Three Years of Imatinib May Halve Death Rate in GIST

(Medscape Medical News) June 8, 2020 - Continuing adjuvant imatinib (Gleevec, Novartis) for 3 years rather stopping at 1 year in patients with high-risk gastrointestinal stromal tumor (GIST) could halve the death rate over 10 years, suggest phase 3 trial data.

read article (free registration required)

Clinical Challenges: Molecular Testing in CRC

(MedPage Today) June 8, 2020 - Consensus on testing for dMMR/MSI-H, but strategies vary for other biomarkers.

read article (free registration required)

Fresh Off ASCO Myeloma Data, Legend Bio Gets $424M In Biotech's Biggest IPO Of 2020

(BioPharma Dive) June 5, 2020 - The China-based cell therapy developer, whose myeloma therapy is a rival to one from Bristol Myers and Bluebird, outraised this year's previous top initial biotech stock offering.

read article

A Bumpy Virtual #ASCO20; Returning to Chicago in 2021?

(Medscape Medical News) June 4, 2020 - The world's largest oncology meeting went online to mixed reviews. Doubts and hopes coexist about an in-person meeting next year.

read article (free registration required)

High Marks for CAR T Cells in R/R Myeloma

(MedPage Today) June 3, 2020 - Response rates of 70-100% with BCMA-targeted products for heavily treated disease.

read article (free registration required)

Autologous TILs Active in Refractory Melanoma

(MedPage Today) June 3, 2020 - Overall response rate of 36% with tumor-infiltrating lymphocytes in heavily treated patients.

read article (free registration required)

At-Home Gene Test for Breast, Ovarian Cancers Looks Effective

(UPI/HealthDay News) June 3, 2020 - Screening for breast and ovarian cancer genes might be added to the list of medical tests that can be safely and effectively done from home, new research suggests.

read article

PPI + Chemo May Reduce Tumors in Rare Breast Cancer

(WebMD/Medscape Medical News) June 2, 2020 - The proton pump inhibitor (PPI) omeprazole used with chemotherapy may help shrink tumors in patients with triple-negative breast cancer.

read article

TRK Inhibitor Continues to Show Multi-Cancer Effects

(MedPage Today) June 2, 2020 - Patients with a variety of cancers -- with a common thread of harboring tropomyosin receptor kinase (TRK) fusion pathology -- responded to treatment with larotrectinib (Vitrakvi), according to research presented at the ASCO virtual meeting.

read article (free registration required)

Second Surgery Gets OS Win in Recurrent Ovarian Cancer

(MedPage Today) June 2, 2020 - Secondary debulking surgery improved overall survival (OS) for select women with recurrent ovarian cancer in first relapse, an updated analysis from the DESKTOP III trial showed, representing the first phase III trial to demonstrate a survival benefit with such an approach.

read article (free registration required)

ASCO 2020 Takeaways: AstraZeneca Does a Star Turn, KRAS Fizzles, and Cell Therapy Shows Progress

(STAT Plus) June 1, 2020 - The annual meeting American Society of Clinical Oncology (ASCO) concluded on Sunday. The closely-followed cancer research meeting is typically held over five days in Chicago. But for the first time, this year’s gathering was conducted entirely virtually due to the coronavirus pandemic. And while it ran for just three days — shorter than the normal five-day conference — there was no shortage of news, from AstraZeneca’s lung cancer results to progress on cell therapies.

read article (paid subscription required)

COVID-19 Could Slow Progress In Reducing Cancer Death, NCI Head Warns

(BioPharma Dive) June 1, 2020 - The spread of COVID-19, and the devastating health impacts the disease can have on patients with cancer, could put at risk years of steady progress in lowering cancer deaths among Americans, the director of the National Cancer Institute warned Saturday. With hospitals across the country stretched thin by COVID-19 cases, cancer care has been disrupted. The risk of coronavirus infection, and the social distancing strictures put in place in response, have made clinical visits, laboratory tests and tumor imaging harder to complete. Many clinical trials — a critical component of treatment for patients with late-stage cancer — were put on pause.

read article

Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program

(Athenex) May 29, 2020 - Athenex, Inc. today presented interim data from an ongoing Phase II clinical trial in which oral paclitaxel and encequidar (“Oral Paclitaxel”, formerly known as Oraxol) monotherapy showed encouraging efficacy and tolerability in elderly patients with unresectable cutaneous angiosarcoma, an aggressive malignancy with poor prognosis.

read corporate press release

Cancer Summit Presses Toward Treatments in Covid’s Shadow

(Bloomberg) May 31, 2020 - The year’s biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations for some closely watched medicines. The American Society of Clinical Oncology meeting is the field’s most important gathering each spring, providing a stage for major pharmaceutical companies to unveil major findings and tout promising treatments. It’s also an annual opportunity for all kinds of researchers, doctors, executives and investors to rub elbows.

read article (free registration required)

ASCO Highlights: Takeda, Genentech, Johnson & Johnson and More

(BioSpace) Jun 1, 2020 - The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights. Takeda Pharmaceutical presented results from the Phase II Pevonedistat-2001 trial at ASCO and the European Hematology Association (EHA) Annual Meeting.

read article

ASCO 2020: UK-first Study Shows Feasibility Of Genetic Screening For Prostate Cancer

(ICR [UK]) Jun 1, 2020 - Genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows. Researchers ‘barcoded’ men for their genetic risk of prostate cancer by testing each for 130 DNA changes – and gave those at higher risk follow-up checks.

read article

VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate

(Markets Insider) Jun 1, 2020 - OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control.

read article

Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program

(Yahoo! Finance) Jun 1, 2020 - First-in-class TIM-based non-gene edited allogeneic CAR-T candidate, CYAD-101, shows encouraging clinical activity with no evidence of graft-versus-host disease in relapsed/refractory metastatic colorectal cancer patients.

read article
Next Page